MedTrace Logo

Treatment of Alcohol Withdrawal in Hospital Patients

NCT00249366 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2016-04-11

No results posted yet for this study

Summary

The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.

Conditions

  • Alcohol Withdrawal Syndrome

Interventions

DRUG

Lorazepam (drug)

Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients

DRUG

Lorazepam

Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Michael F. Weaver, MD · Virginia Commonwealth University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2003-05-31
Completion
2003-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00249366 on ClinicalTrials.gov